Assessment of early epirubicin cardiotoxicity in women with breast cancer

Anticancer Research

Volumn 17, Issue 5 B, 1997, Pages 3889-3891

  Šobić Šaranović, Dragana ^a   Pavlović, Smiljana ^a   Šušnjar, Snežana ^b   Nešković Konstantinović, Zora ^c   Jelić, Svetislav ^b  

^a CLINICAL CENTER OF SERBIA   (Serbia)

^b National Cancer Research Institute   (Yugoslavia)

^c NONE

Author keywords

Breast cancer; Diastolic dysfunction; Epirubicin cadiotoxicity; Radionuclide ventriculography

Indexed keywords

EPIRUBICIN;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLE; FEMALE; HEART DISEASE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; PRIORITY JOURNAL; RADIOISOTOPE VENTRICULOGRAPHY; SYSTOLE;

ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; DIASTOLE; EPIRUBICIN; FEMALE; HUMANS; MIDDLE AGED; SYSTOLE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 2642664515     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Muggia FM, Green MD: New anthracycline antitumor antibiotics. Crit Rev Oncol Hematol 11: 43-64, 1991.
2. Neri B, Cini-Neri G, Bandinelli M et al: Doxorubicin and epirubicin cardiotoxicity: experimental and clinical aspects. Int J Clin Pharmacol Ther Toxicol 27: 217-221, 1989.
3. Callahan RJ, Froelich JW, McKusick KA., et al: A modified method for the in vivo labeling of red blood cells with Tc-99m. J Nucl Med 23: 315-318, 1982.
4. Bacharach SL, Green MV, Borer JS: Instrumentation and data processing in cardiovascular nuclear medicine, evaluation of ventricular function. Semin Nucl Med 9: 257-274, 1979.
5. Caruana M, Khawaja J-AL, Lahiri A, Lewis J, Raftery EB: Radionuclide measurements of diastolic function for assessing early left ventricular abnormalities in the hypertensive patients. Br Heart J 59: 218-226, 1988.
6. Bacharach SL, Green MV, Borer JS, Hyde JE, Farkas SP, Johnston GS: Left ventricular peak ejection rate, filling rate and ejection fraction-frame rate requirements at rest and exercise. J Nucl Med 20: 189-193, 1979.
7. Mirsky J: Assessment of diastolic function: suggested methods and future considerations. Circulation 69: 836-841, 1984.
8. Yamagishi T, Ozaki M, Kumada T, Ikenzo T, Shimizu T, Furutani Y. Asynchronous left ventricular diastolic filling in patients with isolated disease of the left anterior descending coronary artery; assessment with radionuclide ventriculography. Circulation 69, 933-942, 1984.
9. Bianco JA, Filiberti AW, Baker SP et al: Ejection fraction and heart rate correlate with diastolic peak filling rate at rest and during exercise. Chest 88: 107-113, 1985.
10. Valdes Olmos RA, Hoefnagel CA, Van der Schoot JB: Nuclear medicine in the monitoring of organ function and detection of injury related to cancer therapy. Eur J Nucl Med 20: 515-546, 1993.
11. Vorobiof DA, Falkson G, Iturralde MP: Radionuclide angiographic monitoring in patients treated with potentially cardiotoxic cytostatic drugs. S Afr Med J 74: 213-216, 1988.
12. Von Hoff DD, Rozencweig M, Piccart M: The cardiotoxicity of anticancer agents. Semin Oncol 9: 23-33, 1982.
13. Legha SS, Benjamin RS, Mackay B, et al: Reduction of doxorubicin-induced congestive heart failure. Ann Intern Med 96: 133-139, 1982.
14. Billingham ME, Masou JW, Bristow MR, Daniels JR: Antacycline cardiomyopathy monitored by morphological changes. Cancer Treat Rep 62: 865-872, 1978.
15. Torti FM, Bristow MM, Lun BJ, et al: Cardiotoxicity of epirubicin and doxorubicin: assessment by endocardial biopsy. Cancer Res 46: 3722-3727, 1986.
16. Parmentier S, Melin JA, Piret L, et al: Assessment of left ventricular diastolic function in patients receiving anthracycline therapy. Eur J Nucl Med 13: 563-567, 1988
17. Mortensen S.A, Olsen H.S, Baandrup C: Chronic anthracycline cardiotoxicity: haemodynamic and histopathological manifestations suggesting a restrictive endomyocardial disease. Br Heart J 55: 274-282, 1986.